ER stress induces NLRP3 inflammasome activation and hepatocyte death.
Lebeaupin C, Proics E, de Bieville CH, Rousseau D, Bonnafous S, Patouraux S, Adam G, Lavallard VJ, Rovere C, Le Thuc O, Saint-Paul MC, Anty R, Anty R, Schneck AS, Iannelli A, Gugenheim J, Tran A, Gual P, Bailly-Maitre B. · 2015
Read ER stress induces NLRP3 inflammasome activation and hepatocyte death. by Lebeaupin C, Proics E, de Bieville CH, Rousseau D, Bonnafous S, Patouraux S, Adam G, Lavallard VJ, Rovere C, Le Thuc O, Saint-Paul MC, Anty R, Anty R, Schneck AS, Iannelli A, Gugenheim J, Tran A, Gual P, Bailly-Maitre B. (2015) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4650444.txt.
Introduction
Working with colleagues, Cynthia Lebeaupin published a 2015 study on how stress inside liver cells triggers inflammation and cell death in fatty liver disease. Fat build-up in the liver is common in obesity, and a quarter of those patients develop steatohepatitis, which can advance to cancer. The endoplasmic reticulum, the cell's protein workshop, is stressed in obesity. The work appeared in Cell Death and Differentiation.
In obese mouse livers, bacterial toxin or a stress drug switched on two stress sensors, raising a protein called CHOP. CHOP then activated the NLRP3 inflammasome and death programs in liver cells. A drug that relieves the stress blocked the whole chain and rescued cells. Silencing CHOP in isolated liver cells confirmed its central role in the damage.
Catalog record
| CREATOR | Lebeaupin C, Proics E, de Bieville CH, Rousseau D, Bonnafous S, Patouraux S, Adam G, Lavallard VJ, Rovere C, Le Thuc O, Saint-Paul MC, Anty R, Anty R, Schneck AS, Iannelli A, Gugenheim J, Tran A, Gual P, Bailly-Maitre B. |
|---|---|
| YEAR | 2015 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 56 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
ER stress induces NLRP3 inflammasome activation and hepatocyte death By C Lebeaupin, E Proics, C H D de Bieville, D Rousseau, S Bonnafous, S Patouraux, G Adam, V J Lavallard, C Rovere, O Le Thuc, M C Saint-Paul, R Anty Published in: Cell Death & Disease DOI: 10.1038/cddis.2015.248 ABSTRACT Abstract The incidence of chronic liver disease is constantly increasing, owing to the obesity epidemic. However, the causes and mechanisms of inflammation-mediated liver damage remain poorly understood. Endoplasmic reticulum (ER) stress is an initiator of cell death and inflammatory mechanisms. Although obesity induces ER stress, the interplay between hepatic ER stress, NLRP3 inflammasome activation and hepatocyte death signaling has not yet been explored during the etiology of chronic liver diseases. Steatosis is a common disorder affecting obese patients; moreover, 25% of these patients develop steatohepatitis with an inherent risk for progression to hepatocarcinoma. Increased plasma LPS levels have been detected in the serum of patients with steatohepatitis. We hypothesized that, as a consequence of increased plasma LPS, ER stress could be induced and lead to NLRP3 inflammasome activation and hepatocyte death associated with steatohepatitis progression. In livers from obese mice, administration of LPS or tunicamycin results in IRE1α and PERK activation, leading to the overexpression of CHOP. This, in turn, activates the NLRP3 inflammasome, subsequently initiating hepatocyte pyroptosis (caspase-1, -11, interleukin-1β secretion) and apoptosis (caspase-3, BH3-only proteins). In contrast, the LPS challenge is blocked by the ER stress inhibitor TUDCA, resulting in: CHOP downregulation, reduced caspase-1, caspase-11, caspase-3 activities, lowered interleukin-1β secretion and rescue from cell death. The central role of CHOP in mediating the activation of proinflammatory caspases and cell death was characterized by performing knockdown experiments in primary mouse hepatocytes. Finally, the analysis of human steatohepatitis liver biopsies showed a correlation between the upregulation of inflammasome and ER stress markers, as well as liver injury. We demonstrate here that ER stress leads to hepatic NLRP3 inflammasome pyroptotic death, thus contributing as a novel mechanism of inflammation-mediated liver injury in chronic liver diseases. Inhibition of ER-dependent inflammasome activation and cell death pathways may represent a potential therapeutic approach in chronic liver diseases. Nonalcoholic fatty liver disease (NAFLD) has become the most common form of chronic liver disease, currently affecting 20–30% of the general population and 75–100% of obese individuals.1 The spectrum of NAFLD is wide ranging: from hepatic steatosis to nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma. Hepatic steatosis is characterized by triglyceride accumulation in hepatocytes and follows a benign non-progressive clinical course. Nonalcoholic steatohepatitis (NASH), a progressive form, is defined as a combination of lipid accumulation, hepatocyte death, inflammation and fibrosis. As the probability of developing advanced fibrosis and hepatocellular carcinoma2 is significantly greater in patients with steatohepatitis than in those with simple steatosis, it is important to elucidate the mechanism underlying the progression from steatosis to steatohepatitis. The endoplasmic reticulum (ER) stress response has been linked to obesity, type 2 diabetes and liver cancer.3, 4 Under stress conditions, the ER initiates the unfolded protein response (UPR) to restore homeostasis. The UPR involves three transmembrane sensors: inositol-requiring enzyme 1 (IRE1α), PKR-like ER kinase (PERK) and activating transcription factor (ATF6).5 Each pathway culminates in the transcriptional regulation of gene expression, which first seeks to reestablish ER homeostasis. Failure of the UPR to decrease ER stress leads to apoptosis, notably via CHOP, a pro-apoptotic transcription factor whose expression is highly induced by ER stress.6 Increased activation of the ER stress response has been reported in obese mice and humans.3, 4, 7, 8 Obesity results in liver ER stress, which promotes insulin resistance and hepatosteatosis through the IRE1α branch.3 Moreover, PERK and IRE1α can regulate lipid stores in the liver, enforcing the hepatic metabolic disorders associated with obesity.9, 10 It is well established that apoptosis and inflammation are increased in patients with NASH, correlating with histological severity. Because the ER stress response is a critical mediator of inflammation, apoptosis and insulin resistance, it could have a central role in the progression from steatosis to NASH. However, the evidence for activation of hepatic ER stress in patients with NASH needs to be clarified. Gonzalez-Rodriguez et al.11 observed that NASH patients displayed more elevated ER stress markers, namely CHOP and GRP78, reinforcing the notion that enhanced ER stress within liver cells may be relevant in the progression from steatosis to NASH.12, 13, 14 In addition, while studies indicated a contribution of NF-κB in the inflammatory responses triggered as a consequence of hepatic ER stress associated with NASH,15 the potential interplay between ER stress and inflammasome engagement has yet to be explored in NASH progression. The NLRP3 inflammasome is a multi-protein complex which instigates the inflammatory response and contributes to insulin resistance. The NLRP3 inflammasome senses obesity-associated danger signals, namely endotoxin (LPS),16 hyperglycemia and free fatty acids (FFAs), and mediates caspase-1-dependent maturation of the proinflammatory cytokines interleukin-1β (IL-1β) and IL-18.17 Importantly, increased plasma LPS levels have been detected in mice models of NAFLD18 and in humans with NASH.19, 20, 21 Studies have suggested that the NLRP3 inflammasome may have a deleterious role in steatosis and NASH pathogenesis. Indeed, a deficiency in caspase-1, Nlrp3 or ASC in mice results in protection from high-fat diet (HFD)-induced steatosis and insulin resistance.16, 22, 23 Similarly, a deficiency in IL-1β, IL-1 Receptor or TLR424 protects mice from methionine- and choline-deficient (MCD) diet-induced steatohepatitis. Moreover, the NLRP3 inflammasome also triggers pyroptosis, a form of programmed cell death. Pyroptosis is defined as a caspase-1 or caspase-11-dependent cell death subroutine that is associated with the generation of pyrogenic mediators such as IL-1β and IL-18.25, 26 Therefore, the NLRP3 inflammasome could be a major cause of cell death and inflammation in NASH progression. A ‘two hit' mechanism has been proposed to drive NASH pathogenesis.27 The first hit is associated with steatosis and sensitizes the liver to additional proinflammatory insults (second hit), such as LPS, which aggravate liver injury and contribute to the development of NASH.28, 29 We hypothesized that, as a consequence of increased plasma LPS, ER stress could be induced and lead to NLRP3 inflammasome activation and hepatocyte death associated with NASH. To address this issue, we explored in vivo whether the administration of LPS could trigger exaggerated hepatic ER stress signaling, and compared the response with that of tunicamycin, a chemical ER stress inducer, in steatotic livers from genetically obese (ob/ob) mice. We analyzed the potential benefit of TUDCA, an ER stress inhibitor, in the prevention and treatment of hepatic inflammation and death caused by an LPS challenge. We found that PERK and IRE1α pathways cooperate to activate CHOP, and that this appears to be a critical link between inflammasome activation and hepatocyte death in NASH. Importantly, the upregulation of transcripts of ER stress correlated with inflammasome priming and liver injury in NASH patients, which highlights their relevance in disease progression. RESULTS TUDCA protects the liver from LPS-induced injury, apoptosis and inflammasome priming In genetically obese mice (ob/ob) with severe steatosis and challenged with LPS, we investigated the in vivo effects of TUDCA treatment. Liver histological analysis revealed severe inflammation with many inflammatory foci and areas of cell death in LPS-injected mice compared with PBS-injected mice (Figure 1a). Five days of TUDCA treatment dramatically reduced the number of steatohepatitis foci (presence of inflammatory